Clinical and Genetic Characteristics of 23 Korean Patients with Haploinsufficiency of the Short-stature Homeobox-containing Gene

Abstract

Background The short-stature homeobox-containing gene (SHOX) is one of the major growth genes in humans. The clinical spectrum of SHOX haploinsufficiency ranges from Léri–Weill dyschondrosteosis to idiopathic short stature. Herein, we describe the clinical and genetic characteristics of 23 Korean patients with SHOX deficiency disorders.

Methods Medical records of 23 patients (19 females and 4 males) from 15 unrelated families who were genetically confirmed to have SHOX deficiency were retrospectively reviewed. SHOX gene deletions or mutations were determined by sequence analyses using multiplex ligation-dependent probe amplification, chromosomal microarray, and/or Sanger sequencing methods.

Results In the 15 families, 9 probands were de novo cases. All 23 patients showed mesomelia. Madelung deformity and tibia vara were observed in 13 (56.5%) and 3 (13.1%) patients, respectively. Genetically, 11 (73.3%) of the 15 families showed SHOX deletions of various sizes, and the other 4 families harboured SHOX sequence variants. Four patients had undergone orthopaedic surgeries (3 for tibia vara and 1 for Madelung deformity). Among 7 patients who had received growth hormone treatment for ≥1 year, 5 showed good responses, with a median first-year change-in-height standard deviation score of +0.6. There were no significant differences in the clinical characteristics of the deletion and point mutation groups.

Conclusions A high index of suspicion and the genetic confirmation of SHOX deficiency are helpful for the timely management of the condition and are needed to provide genetic counselling to the family members of the patients.

Key words

SHOX deficiency - Léri-Weill dyschondrosteosis - haploinsufficiency - Madelung deformity - mesomelia

Publication History

Received: 29 April 2020
Received: 14 July 2020

Accepted: 24 August 2020

Article published online:
15 September 2020

• References

• 1 G B. Short stature due to SHOX Deficiency: Genotype, phenotype, and therapy. Horm Res Paediat 2011; 81-89
• 2 Genoni G, Monzani A, Castagno M. et al. Improving clinical diagnosis in SHOX deficiency: The importance of growth velocity. Pediatr Res 2018; 83: 438-444
• 3 Huber C, Rosilio M, Munnich A. et al. High incidence of SHOX anomalies in individuals with short stature. J Med Genet 2006; 43: 735-739
• 4 Rosilio M, Huber-Lequesne C, Sapin H. et al. Genotypes and phenotypes of children with SHOX deficiency in France. J Clin Endocrinol Metab 2012; 97: E1257-E1265
• 5 Rappold G, Blum WF, Shavrikova EP. et al. Genotypes and phenotypes in children with short stature: Clinical indicators of SHOX haploinsufficiency. J Med Genet 2007; 44: 306-313
• 6 Clement-Jones M, Schiller S, Rao E. et al. The short stature homeobox gene SHOX is involved in skeletal abnormalities in Turner syndrome. Hum Mol Genet 2000; 9: 695-702
• 7 Fukami M, Kato F, Tajima T. et al. Transactivation function of an approximately 800-bp evolutionarily conserved sequence at the SHOX 3′ region: Implication for the downstream enhancer. Am J Hum Genet 2006; 78: 167-170
• 8 Fukami M, Seki A, Ogata T. SHOX haploinsufficiency as a cause of syndromic and nonsyndromic short stature. Mol Syndromol 2016; 7: 3-11
• 9 Cohen P, Rogol AD, Deal CL. et al. Consensus statement on the diagnosis and treatment of children with idiopathic short stature: a summary of the Growth Hormone Research Society, the Lawson Wilkins Pediatric Endocrine Society, and the European Society for Paediatric Endocrinology Workshop. J Clin Endocrinol Metab 2008; 93: 4210-4217
• 10 Choi WB, Seo SH, Yoo WH. et al. A Leri-Weill dyschondrosteosis patient confirmed by mutation analysis of SHOX gene. Ann Pediatr Endocrinol Metab 2015; 20: 162-165
• 11 Kim JH, Yun S, Hwang SS. et al. The 2017 Korean National Growth Charts for children and adolescents: Development, improvement, and prospects. Korean J Pediatr 2018: 135-149
• 12 Bloem M. The 2006 WHO Child Growth Standards. BMJ 2007; 334: 705-706
• 13 Styne DM, Arslanian SA, Connor EL. et al. Pediatric obesity-assessment, treatment, and prevention: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2017; 102: 709-757
• 14 Pandey S, Pandey KA. Clinical Orthopedic Diagnosis. 4 ed. Jaypee Brothers, Medical Publishers Pvt. Limited; 2018
• 15 Rungprai C, Goetz JE, Arunakul M. et al. Validation and reproducibility of a biplanar imaging system versus conventional radiography of foot and ankle radiographic parameters. Foot Ankle Int 2014; 35: 1166-1175
• 16 Tanner JM, Goldstein H, Whitehouse RH. Standards for children’s height at ages 2-9 years allowing for heights of parents. Arch Dis Child 1970; 45: 755-762
• 17 Bayley N, Pinneau SR. Tables for predicting adult height from skeletal age: revised for use with the Greulich-Pyle hand standards. J Pediatr 1952; 40: 423-441
• 18 Bang P, Bjerknes R, Dahlgren J. et al. A Comparison of Different Definitions of Growth Response in Short Prepubertal Children Treated with Growth Hormone. Horm Res Paediat 2011; 75: 335-345
• 19 Shears DJ, Guillen-Navarro E. et al. Pseudodominant inheritance of Langer mesomelic dysplasia caused by a SHOX homeobox missense mutation. Am J Med Genet 2002; 110: 153-157
• 20 Wolters B, Lass N, Wunsch R. et al. Short stature before puberty: which children should be screened for SHOX deficiency?. Horm Res Paediatr 2013; 80: 273-280
• 21 Jin-Sang Chung J-RK, Hee-Kyu Kwon, Chung-Hie Oh. Arm and Forearm Measurement in Korean. J Korean Acad Rehabil Med 1985; 9: 50
• 22 Shapiro F. Pediatric Orthopedic Deformities. Elsevier Science; 2002: 813 p
• 23 Fukami M, Nishi Y, Hasegawa Y. et al. Statural growth in 31 Japanese patients with SHOX haploinsufficiency: Support for a disadvantageous effect of gonadal estrogens. Endocr J 2004; 51: 197-200
• 24 Ghatan AC, Hanel DP. Madelung deformity. J Am Acad Orthop Surg 2013; 21: 372-382
• 25 Aza-Carmona M, Shears DJ, Yuste-Checa P. et al. SHOX interacts with the chondrogenic transcription factors SOX5 and SOX6 to activate the aggrecan enhancer. Hum Mol Genet 2011; 20: 1547-1559
• 26 Binder G, Ranke MB, Martin DD. Auxology is a valuable instrument for the clinical diagnosis of SHOX haploinsufficiency in school-age children with unexplained short stature. J Clin Endocr Metab 2003; 88: 4891-4896
• 27 Benito-Sanz S, Barroso E, Heine-Suner D. et al. Clinical and molecular evaluation of SHOX/PAR1 duplications in Leri-Weill dyschondrosteosis (LWD) and idiopathic short stature (ISS). J Clin Endocrinol Metab 2011; 96: E404-E412
• 28 Benito-Sanz S, Aza-Carmona M, Rodriguez-Estevez A. et al. Identification of the first PAR1 deletion encompassing upstream SHOX enhancers in a family with idiopathic short stature. Eur J Hum Genet 2012; 20: 125-127
• 29 Hinch AG, Altemose N, Noor N. et al. Recombination in the human Pseudoautosomal region PAR1. PLoS Genet 2014; 10: e1004503
• 30 Bunyan DJ, Baker KR, Harvey JF. et al. Diagnostic screening identifies a wide range of mutations involving the SHOX gene, including a common 47.5 kb deletion 160 kb downstream with a variable phenotypic effect. Am J Med Genet A 2013; 161A: 1329-1338
• 31 Schneider KU, Marchini A, Sabherwal N. et al. Alteration of DNA binding, dimerization, and nuclear translocation of SHOX homeodomain mutations identified in idiopathic short stature and Leri-Weill dyschondrosteosis. Hum Mutat 2005; 26: 44-52
• 32 Richards S, Aziz N, Bale S. et al. Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 2015; 17: 405-424
• 33 Binder G, Renz A, Martinez A. et al. SHOX haploinsufficiency and Leri-Weill dyschondrosteosis: Prevalence and growth failure in relation to mutation, sex, and degree of wrist deformity. J Clin Endocrinol Metab 2004; 89: 4403-4408
• 34 Chen J, Wildhardt G, Zhong Z. et al. Enhancer deletions of the SHOX gene as a frequent cause of short stature: The essential role of a 250 kb downstream regulatory domain. J Med Genet 2009; 46: 834-839
• 35 Donze SH, Meijer CR, Kant SG. et al. The growth response to GH treatment is greater in patients with SHOX enhancer deletions compared to SHOX defects. Eur J Endocrinol 2015; 173: 611-621
• 36 Blum WF, Crowe BJ, Quigley CA. et al. Growth hormone is effective in treatment of short stature associated with short stature homeobox-containing gene deficiency: Two-year results of a randomized, controlled, multicenter trial. J Clin Endocrinol Metab 2007; 92: 219-228
• 37 Scalco RC, Melo SS, Pugliese-Pires PN. et al. Effectiveness of the combined recombinant human growth hormone and gonadotropin-releasing hormone analog therapy in pubertal patients with short stature due to SHOX deficiency. J Clin Endocrinol Metab 2010; 95: 328-332
• 38 Benabbad I, Rosilio M, Child CJ. et al. Safety outcomes and near-adult height gain of growth hormone-treated children with shox deficiency: Data from an observational study and a clinical trial. Horm Res Paediatr 2017; 87: 42-50